Skip to content
Search

Latest Stories

Bolton locum pharmacist receives three-month suspension for workplace sexual misconduct

The Fitness-to-Practise Committee of the General Pharmaceutical Council has issued a three-month suspension to Mohammed Roohul Haque (Reg No: 2226084), a locum pharmacist, due to incidents of workplace sexual misconduct.

According to the determination document issued by the regulatory body, Haque undertook the position of a locum pharmacist at Hollowood Chemists on July 12. It was during this period that he encountered the dispenser (referred to as the "complainant"), a 40-year-old co-worker at the pharmacy, for the first instance. Following this initial meeting, he proceeded to engage in making explicit sexual comments.


During the lunch break of the pharmacy's second dispenser, Haque asked the dispenser, who had lodged the complaint, to review photographs displayed on his mobile phone, depicting renovations being carried out at his residence. The initial images focused on the ongoing renovation activities. However, he later switched to displaying a full-screen photograph of his erect penis, the document said.

Despite the fact that the dispenser promptly distanced herself, Haque persisted in discussing the photograph with her. He went so far as to apologise, and even asked if she had managed to closely observe the picture.

On the following day, July 13, 2021, the dispenser filed a formal complaint regarding Haque's misconduct with Hollowood's superintendent pharmacist. She also indicated her intention to report the incident to the General Pharmaceutical Council (GPhC), as mentioned in the document.

The case hearing took place from July 24 to 26.

Haque conceded to displaying a photograph of his erect penis to the dispenser, along with making remarks concerning her physical appearance. He acknowledged that his actions were inappropriate. However, he labelled the comments as banter and contended that he had unintentionally accessed the explicit picture, as detailed in the document.

The Committee, however, found Haque's explanation less convincing given the case's facts. He stated his comments were aimed at establishing a positive working relationship, but this contradicted evidence that he spent most of the morning on his mobile phone rather than assisting in the dispensary, as noted by the Committee.

It also took into consideration the Council's publication "Good decision-making" (revised March 2017) to understand the concept of 'fitness to practise’. Paragraph 2.11 reads: “A pharmacy professional is ‘fit to practise’ when they have the skills, knowledge, character, behaviour and health needed to work as a pharmacist…safely and effectively. In practical terms, this means maintaining appropriate standards of competence, demonstrating good character, and also adhering to the principles of good practice set out in your various standards, guidance and advice.”

The Committee reached the conclusion that Haque had intentionally displayed the image with the aim of seeking sexual satisfaction or pursuing a sexual connection. It further stated that he had misused his professional status, given that the individual impacted by his misconduct was a subordinate.

It further noted that Haque's misconduct was tempered by the fact that it occurred on a single day and did not involve any physical contact. As outlined in its decision, this placed the sexual misconduct at the less severe end of the spectrum.

The Committee found the allegations amounted to misconduct and chose to suspend Haque from the registry for three months, as detailed in the document. It also noted that a brief suspension period sufficed to signify the gravity of the registrant's inappropriate sexual behaviour, given his authentic understanding, remorse, and meaningful actions taken to address the matter.

Meanwhile, a noticeable shift in community pharmacy work patterns is occurring, with a greater reliance on locum pharmacists in the staffing model, according to 2022 Community Pharmacy Workforce Survey by NHS England. While employed pharmacists decreased by 16 per cent from 12,774 in 2021 to 10,943 in 2022, locum pharmacists increased by 26 per cent from 4,297 in 2021 to 5,477 in 2022. This trend persists even though locum pharmacists, on average, work fewer hours.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less